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Beside functional and structural changes in vascular bi-
ology, alterations in the rheologic properties of blood cells
mainly determines to an impaired microvascular blood
ﬂow in patients suffering from diabetes mellitus. Recent
investigations provide increasing evidence that impaired
C-peptide secretion in type 1 diabetic patients might con-
tribute to the development of microvascular complica-
tions. C-peptide has been shown to stimulate endothelial
NO secretion by activation of the Ca2+ calmodolin reg-
ulated enzyme eNOS. NO himself has the potency to in-
crease cGMP levels in smooth muscle cells and to activate
Na+K+ATPase activity and therefore evolves numerous ef-
fectsinmicrovascularregulation.Intype1diabeticpatients,
supplementation of C-peptide was shown to improve en-
dothelium dependent vasodilatation in an NO-dependent
pathway in different vascular compartments. In addition,
it could be shown that C-peptide administration in type 1
diabetic patients, results in a redistribution of skin blood
ﬂow by increasing nutritive capillary blood ﬂow in favour
to subpapillary blood ﬂow. Impaired Na+K+ATPase in an-
other feature of diabetes mellitus in many cell types and
is believed to be a pivotal regulator of various cell func-
tions. C-peptide supplementation has been shown to re-
store Na+K+ATPase activity in different cell types during
in vitro and in vivo investigations. In type 1 diabetic pa-
tients, C-peptide supplementation was shown to increase
erythrocyte Na+K+ATPase activity by about 100%. There
was found a linear relationship between plasma C-peptide
levels and erythrocyte Na+K+ATPase activity. In small
capillaries, microvascular blood ﬂow is increasingly deter-
mined by the rheologic properties of erythrocytes. Using
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laser-diffractoscopieahugeimprovementinerythrocytede-
formability could be observed after C-peptide administra-
tion in erythrocytes of type 1 diabetic patients. Inhibition
of the Na+K+ATPase by Obain completely abolished the
effect of C-peptide on erythrocyte deformability. In conclu-
sion,C-peptideimprovesmicrovascularfunctionandblood
ﬂow in type 1 diabetic patients by interfering with vascular
and rheological components of microvascular blood ﬂow.
Keywords C-peptide; Microvascular Blood Flow; Nitric Oxide;
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INTRODUCTION
Pathophysiology of Vascular Complications
in Diabetes Mellitus
Since the discovery of insulin in 1922 by Banting and Best,
the most frequent complications of type 1 diabetes mellitus
have changed from acute metabolic disturbances to the long-
term complications retinopathy, nephropathy, and neuropathy.
Although hyperglycemia is recognized as an important patho-
genetic factor in the development of these diabetic complica-
tions, the precise mechanisms whereby diabetes precipitates
these complications, are still largely unknown. Furthermore, it
is well-known also that in type 1 diabetic patients with good
metaboliccontrol,microvascularcomplicationscannotbesufﬁ-
ciently prevented. Therefore, the possibility may be considered
that other factors than the lack of insulin secretion or the ele-
vatedbloodglucoselevelsmightbeinvolvedinthepathogenesis
of diabetic complications.
Numerous functional and structural microvascular distur-
bances have been reported for patients suffering from type 1
diabetes. These microvascular disturbaces are thought to be
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implicated in the development of diabetic complications, such
as retinopathy, neuropathy, and nephropathy, and the develop-
mentoffootskinulceration.Themicrocirculationisconcerned
with the transport and exchange of nutrients and waste prod-
ucts of metabolism, tissue defense and repair, and the often
conﬂicting demand of maintenance tissue ﬂuid economy. Early
type 1 diabetes is characterized by increased microvascular
blood ﬂow, increased shear stress, and tangential pressure on
microvascular endothelium. In consequence, microvascular
sclerosis occurs, involving basement membrane thickening as
well as arteriolar hyalinosis, which limits the capacity of the
microvasculaturetodilateattimesofincreaseddemand(Tooke,
1999). The etiology of diabetic microvascular dysfunction is
not fully understood, but several mechanisms that appear to
act synergistically as pathogenetic factors in the setting of mi-
crovascular blood ﬂow regulation are discussed. In addition to
functional abnormalities of the microvasculature, such as dis-
turbedneurovascularresponses(Forstetal.,1997;Nettenetal.,
1996), alterations in endothelial function (Johnstone et al.,
1993), and an increased intracapillary pressure (Sandemann
et al., 1992), several hemorheological disturbances have been
described in patients with diabetes mellitus. An increase in
leucocyte-endothelial interactions (Kunt et al., 1998a), in-
creased blood viscosity (Ernst and Matrai, 1986; Barnes et al.,
1977), and changes in the rheologic properties of red blood
cells (Finotti and Palatini, 1986; McMillan et al., 1998) may
contribute to the observed microvascular alterations in blood
ﬂow. These early microvascular and hemorheological abnor-
malities may precede structural vascular changes, which occur
later in the course of the microvascular disease (Rayman et al.,
1995).
Pathophysiology of Vascular Endothelium
in Diabetes Mellitus
A hypothesis of the initial event of microvascular disease
is endothelial dysfunction, deﬁned pragmatically as changes in
the concentration of the chemical messangers produced by the
endothelial cell. (Calles-Escandon and Cipolla, 2001). The en-
dothelial cell lines the internal lumen of the vasculature and
serves as an interface between circulating blood and vascular
smooth muscle cell. In addition to serving as a physical bar-
rier between the blood and tissues, the endothelial cell facili-
tates a complex array of functions in intimate interaction with
the vascular smooth muscle cell, as well as cells within the
blood stream. There are several substances released from the
endothelial cells under physiologic circumstances that modify
the vascular tone, e.g., nitric oxide (NO), prostaglandins, and
manyotherpeptides,suchasthrombin,substanceP,bradykinin,
serotonin, etc. (Colwell and Lopes-Virella, 1988).
The most important ﬁnding concerning the physiology of
vascular tone was the discovery of the so-called endothe-
lium derived relaxing factors (EDRF) by Robert Furchgott and
coworkers in 1980 (Furchgott and Zawadzki, 1980). They were
abletodemonstratethatringsofisolatedrabbitaortacontracted
withphenylephrinefailedtorelaxafteradministrationofacetyl-
choline if the intimal layer, i.e., the endothelium, was removed
from the blood vessel mechanically prior to the investigation.
Moreover, NO was identiﬁed as the primary vasodilator re-
leased from the endothelium (Palmer et al., 1987). Endoge-
neous NO is produced within the endothelial cell through the
conversion of the amino acid L-arginine to L-citrulline by the
enzyme endothelial NO synthase (eNOS), one of several iso-
forms of the enzyme. eNOS is regulated by Ca2+-calmodulin
withNADPH.NOproducedbytheendothelialcelldiffusesinto
the blood stream and to the vascular smooth muscle cell. In the
vascular smooth muscle cell, it activates the enzyme guanylate
cyclase, leading to an increase in cyclic GMP with subsequent
vasorelaxation (Figure 1).
Many agonists, such as acetylcholine, are able to initiate
the release of NO by increasing the endothelial cell calcium
(Danthuluri et al., 1988). This can be mediated by receptor
activationofphospholipaseC,withthesubsequentformationof
inositoltriphosphateandreleaseofintracellularcalciumstores,
and by enhancing the inﬂux of extracellular calcium as well;
e.g., in an experimental model, the ionophore A23187 is able
to increase the level of intracellular calcium without involving
endothelial receptors (Peach et al., 1987).
Studiesintheﬁeldofdiabetologyhavealwaysbeenfocusing
especially on the effect of hyperglycemia on vascular dysfunc-
tion. There is evidence that the abnormality of the endothe-
lium in diabetes mellitus results from abnormal production of
vasoconstrictor prostaglandins because this dysfunction could
be normalized by cyclooxygenase inhibitors or by inhibition
of thromboxane A2/prostaglandin H2 receptors (Tesfamariam
et al., 1989).
Early studies suggested that hyperglycemia may contribute
to vascular dysfunction by enhanced synthesis of sorbitol via
the aldose reductase pathway, causing depletion of the intra-
cellular pool of myo-inositol (Greene et al., 1987). Inhibition
of aldose reductase as well as addition of myo-inositol in an
aortic ring model resulted in a normal endothelium-dependent
relaxation in response to acetylcholine. It is tempting to spec-
ulate that this depletion of myo-inositol decreases the turnover
of phosphatidylinositol, which is involved in the regulation of
Na+,K+-ATPase.
Na+,K+ATPase activity has been found to be attenuated
in various cell types under diabetic conditions (Wald et al.,
1993; Gerbi et al., 1997; Vague et al., 1997). It has also been
shown that hyperglycemia inhibits Na+,K+-ATPase activity byC-PEPTIDE AND BLOOD FLOW AND HEMORHEOLOGY 53
FIGURE 1
Mechanism of endothelial nitric oxide synthesis and subsequent vasorelaxation.
an endothelium dependent pathway (Simmons et al., 1986).
Na+,K+-ATPase is a plasma membrane–associated protein
complex that is expressed in most eukaryotic cells. It couples
the energy released in the intracellular hydrolysis of ATP to the
transport of cellular ions, a major pathway for the controlled
translocation of sodium and potassium ions across the cell me-
brane. Therefore, Na+,K+-ATPase is able to control directly or
indirectly many essential cellular functions, e.g., cell volume,
freecalciumconcentrations,andmembranepotential(Roseand
Valdes, Jr., 1994). Although there are tissue differences and
tissue-speciﬁc regulations of Na+,K+-ATPase activity, hyper-
glycemia and diabetes are predominantly characterized by a
decrease of ouabain-sensitive Na+,K+-ATPase activity, lead-
ing to disturbances of main cellular mechanisms (see above),
e.g., to an increased intracellular calcium level and to increased
vascular contractility, both of which promoting vascular com-
plications in diabetes mellitus.




have been shown to increase vascular Na+,K+ATPase activity,
with subsequent vasorelaxation (Gupta et al., 1994; Rand and
Garland, 1992).
The impairment of Gi-proteins also seems to be a common
mechanism of vascular dysfunction in diabetes mellitus; e.g.,
Gi-protein is deﬁcient in streptozotocin-induced diabetic rats
(Gawler et al., 1987). Pertussis toxin, which is able to in-
activate Gi-protein by ADP ribosylation, inhibits the vascu-
lar relaxation caused by acetylcholine. Actually, the impair-
ment of vascular relaxation due to pertussis toxin appears to
be very similar to the vascular dysfunction caused by hyper-




(Lee et al., 1989). King and colleagues were able to demon-
strate that phorbol myristate acetate (PMA) exerts a similar
effect on endothelial cell function as seen after exposure to
high concentrations of glucose. For example, PMA was able to
increase the acetylcholine-induced release of vasoconstrictor
prostaglandins in isolated rabbit aortic rings. Moreover, this in-
creased release of vasoconstricor prostaglandins was prevented
byadditionofPKCinhibitors.TheactivationofPKC,inturn,in-
activatesGi-proteinbyphosphorylation.Hence,itisverylikely
that this mechanism may be responsible for the vascular dys-
function caused by hyperglycemia in diabetes mellitus.
In summary, there is increasing evidence concerning the
underlying mechanisms of vascular dysfunction in diabetes
mellitus, especially under hyperglycemic conditions. In con-
trast, there has been almost no evidence so far that explains
vascular dysfunction in diabetes mellitus in the absence of hy-
perglycemia. This is the ﬁeld of research, predominantly deal-
ing with type 1 diabetes, where the investigation of the role of
C-peptide deﬁciency may play a signiﬁcant role and is worth
following up.54 T. FORST AND T. KUNT
IN VITRO INVESTIGATIONS
Effect of C-peptide on eNOS
The vasodilator effect of insulin (Flynn et al., 1992; Tooke
et al., 1985a) has previously been linked to the release of NO
from endothelial cells, and a decreased endothelial NO pro-
duction has been seen in diabetes (Forstermann et al., 1994;
Moncada and Higgs, 1993). Therefore, we hypothesized that
the vascular effects of C-peptide could also be related to the
endothelial NO system. In accordance with the immediate on-
set of the vasodilator effects of C-peptide in vivo (Kunt et al.,
1999), we initiated an in vitro study using a reporter cell assay
in order to evaluate the possible effect of C-peptide on the ac-
tivation of eNOS. We were able to demonstrate that C-peptide
signiﬁcantly enhanced the release of NO from bovine aortic
endothelial cells (BAECs) (Figure 2). The effect of C-peptide
inthisstudywasdosedependentandtherequireddosesforthis
stimulation have been in a physiological range of 1 to 6 nM.
These ﬁndings are in accordance to the results of Jensen
and Messina (1999) who demonstrated a vasodilatory effect
of C-peptide in isolated rat cremaster muscle arterioles, which
was sensitive to NG-nitro-L-arginine (L-NNA) inhibition, but
in contrast to our results, the response of C-peptide was only
observed in the presence of insulin.
Furthermore, it should be mentioned that in our study, the
stimulation of NO was performed by stimulating BAECs with
human C-peptide despite the fact that the whole C-peptide
FIGURE 2
Effect of C-peptide on NO production in endothelial cells.
There was a signiﬁcant, almost 2-fold increase of NO
production after incubation of bovine aortic endothelial cells
with 6.6 nM C-peptide and evaluation in a reporter cell assay
(RFL-6 cells). This activation of NO synthase could be
blocked by addition of NG-nitro-L-arginine (L-NNA) or in
Ca2+-free medium. 100% is equivalent to 5.01 ± 1.41 pmol
cGMP/106 RFL-6 cells. Each column represents the mean ±
SEM of 4 experiments (∗∗∗P <. 001 versus control).
molecule varies largely in both species. Therefore, it is
noteworthy that the C-terminal pentapeptide reveals apparently
speciﬁc effects on Na+,K+-ATPase activity and shows partial
homology between different species (Ohtomo et al., 1998).
Moreover, recent studies of our group revealed that the
C-terminal pentapeptide exerts similar effects compared to the
whole peptide in this NO reporter cell assay and in the ery-
throcyte deformability assay as well, whereas non–C-terminal
segments or a scrambled C-peptide showed no effect (Kunt
et al., 1999; Hach et al., 2002).
C-peptide increased the intracellular Ca2+ concentration
in BAECs (Figure 3). Both the C-peptide–stimulated Ca2+
signal and the NO release were abolished in Ca2+-free medium
because the endothelial eNOS is a Ca2+-calmodulin–regulated
enzyme (Forstermann et al., 1991), and the peptide is likely
to stimulate eNOS activity by facilitating an inﬂux of Ca2+
into BAECs (Figure 3). C-peptide has previously been shown
to increase Ca2+ inﬂux into renal tubular cells (Ohtomo et al.,
1998), but similar data with endothelial cells have not been
publishedasyet.InviewoftheimportantcontributionofeNOS
to the regulation of vascular resistance and blood pressure in
vivo (Huang et al., 1995), a twofold increase in NO release is
likely to have signiﬁcant hemodynamic consequences.
Human endothelial cells in culture tend to loose their re-
sponsiveness to peptides very rapidly. Even human umbilical
vein endothelial cells (HUVECs), which can be used at early
passages, are much less reliable than BAECs in their response
to receptor-mediated stimulation of NO release (Forstermann
et al., 1989). Nevertheless, we repeated our experiments with
HUVECs. As expected, the NO release from HUVECs in re-
sponse to C-peptide (6.6 nM) was quite variable, with some
FIGURE 3
C-peptide–induced calcium inﬂux into endothelial cells.
Addition of C-peptide to bovine aortic endothelial cells
yielded in a signiﬁcant increase of calcium inﬂux into the
endothelial cells (measured by Fluo-3 technique).C-PEPTIDE AND BLOOD FLOW AND HEMORHEOLOGY 55
batches of cells showing no signiﬁcant NO production at all.
Only freshly isolated cells showed measurable Ca2+ inﬂux and
NO release in response to C-peptide. These data suggest that
HUVECs in culture rapidly down-regulate or loose the bind-
ing site (receptor) for C-peptide. Also, Rigler and colleagues
(1999) were unable to demonstrate speciﬁc membrane binding
of C-peptide in cultures of HUVECs, but did show such bind-
ing in human saphenous vein endothelial cells, ﬁbroblasts, and
renal tubular epithelial cells.
The NO release from BAECs was smaller when the cells
wereexposedtothepeptidefor30minutesthanaftera2-minute
incubation.Thistransienteffectsuggestsadesensitizationofthe
potential receptor (or the subsequent signaling cascade), which
has been also demostrated for other peptide stimulators of en-
dothelial NO release (Forstermann et al., 1988). Moreover, en-
dothelialcellshavetobeculturedatleast12hoursinserum-free
medium in order to obtain a signiﬁcant NO response (authors’
own observations) because the potential C-peptide binding site
seemstobesaturatedatlowconcentrations,whicharecertainly
exceeded if the culture medium is supplemented with serum.
Again, the study of Rigler and colleagues (1999) conﬁrms this
observation by demonstrating a competitive displacement of
C-peptide at the binding site at very low concentrations.
In the same study, we were able to show by means of
quantitative reverse transcriptase–polymerase chain reaction
(RT-PCR) that the levels of eNOS mRNA are unlikely to be
modulated by human C-peptide. This is in agreement with the
immediateonsetofthevasculareffectofC-peptide,whichcould
nothavebeenexplainedbyachangeintheexpressionofeNOS.




ther strengthens the view that C-peptide indeed has biological
effects.
C-peptide and Red Cell Deformability
Diabetes mellitus is associated with morphological and
functional alterations in microcirculation, heavily affecting
hemorrheology. Beside increased capillary shunt ﬂow due to
peripheral diabetic neuropathy of the C ﬁbers (Corbin et al.,
1987), attenuated axon reﬂex response (Benarroch and Low,
1991) and increased leukocyte-endothelial interaction due
to stimulated leukocyte integrins and endothelial adhesion
molecules (Ruggiero et al., 1997; Kunt et al., 1998a), alter-
ation of blood viscosity (Ernst and Matrai, 1986) is an impor-
tant component of the hypothesis concerning the underlying
mechanisms. Blood ﬂow in larger vessels is determined by the
vessel diameter, the viscosity (erythrocyte deformability and
whole blood viscosity), and vessel length according to the law
of Hagen-Pouiseuille. In smaller vessels of the microvascula-
ture, especially if the diameter of the vessel is smaller than the
diameter of the erythrocytes, as found in capillaries, blood ﬂow
is predominantly determined by the viscosity and deformabil-
ity of the erythrocytes. Thus, reduced deformability leads to
reduced ﬂow in microcirculation if the capillary diameter and
blood pressure remain constant (Chien, 1987).
The rheologic properties of erythrocytes in diabetes melli-
tus have been the subject of numerous studies. These studies
demostrated that several factors, such as decreased erythrocyte
deformability,increasederythrocyteaggregation,andincreased
membrane microviscosity, contribute to alterations of the rhe-
ological properties (Ernst and Matrai, 1986; Bareford et al.,
1986; Finotti and Palatini, 1986; Chimori et al., 1986; Cohen
et al., 1976; McMillan et al., 1998; Baba et al., 1979; Schmid-
SchonbeinandVolger,1976)thatarerelatedtothemodiﬁcation
of proteins and lipids by advanced glycation end products, to
the generation of free oxygen radicals, and to changes in ion
homeostasis by hyperglycemia.
Concerning the possible mechanism of reduced erythrocyte
deformability, it is noteworthy that Na+,K+-ATPase activity
has been shown to be attenuated in several cell types, including
erythrocytes in diabetes patients (Ohtomo et al., 1996, 1998;
Finotti and Palatini, 1986) and that it may be restored not only
by insulin, but C-peptide as well (Ohtomo et al., 1996). This
fact is considered to be of clinical importance because some
type 1 diabetes patients maintain a measurable level of beta
cell activity for many years, and the frequency of microvascu-
lar lesions in these patients is negatively correlated to residual
islet cell function (Sjoberg et al., 1987; Kernell et al., 1990).
These ﬁndings have generally been interpreted as indicating
that remaining beta cell secretion of (endogenous) insulin ex-
erts a beneﬁcial effect on glycemic control. However, it is not
apparent why endogenous insulin should be more protective
than exogenous insulin.
These ﬁndings concerning the microcirculatory effects of
C-peptide led to the suggestion that the peptide may also in-
ﬂuence the rheologic properties of erythrocytes. Therefore, we
investigatedthedeformabilityoferythrocytesintype1diabetes
patients,i.e.,C-peptide–deﬁcientsubjects,comparedtohealthy
controls. Both groups were matched concerning their glucose
levels in order to exclude a glucotoxic effect. Deformability
was tested under physiological (0.3 to 10 Pa) and supraphysi-
ological (>10 Pa) shear stress rates by means of laser diffrac-
toscopy.Theerythrocytedeformabilitywasconsiderablylower
in the diabetic group (Figure 4), e.g., at a physiological shear
rate of 7.1 Pa, from E = 0.4306 ± 0.006 to E = 0.3794 ± 0.023
(P = .002).
During another study, erythrocytes from healthy controls
and type 1 diabetes patients were incubated with different56 T. FORST AND T. KUNT
FIGURE 4
Measurement of elongation index E in diabetic patients and controls. Compared to healthy controls (), the elongation index E of
the erythrocytes was considerably lower (P <. 0001) in type 1 diabetes patients () at all tested shear rates. Statistical analysis
was performed by 2-site ANOVA.
concentrations of C-peptide comparable to basal physiologi-
cal (0.6 nM), postprandial physiological (6.6 nM), and supra-
physiological (66.6 nM) levels. Interestingly, administration of




Representative analysis of erythrocyte deformability at 1.75 Pa. This graph shows the alterations of elongation index E at a shear
stress of 1.75 Pa, which is frequently achieved in vivo. C-peptide did not modify the deformability of erythrocytes obtained from
healthy controls, whereas the deformability of diabetic erythrocytes was restored to normal levels after administration of different
concentrations of the peptide. Statistical analysis was performed by Student’s t test.
groups (Figure 5). In contrast, proinsulin C-peptide had no ad-
ditional effect on the deformability of erythrocytes in healthy
controls. This might be explained by the fact that the control
patients naturally revealed basal serum C-peptide levels, which
were shown to exert already maximal effects on deformabil-
ity in the present study. In agreement with these ﬁndings, theC-PEPTIDE AND BLOOD FLOW AND HEMORHEOLOGY 57
missing effect of proinsulin C-peptide on skin microcirculation
innondiabeticcontrolsubjectsisworthmentioning(Forstetal.,
1998).
Furthermore, different concentrations of C-peptide were
foundtoexertsimilareffectsonerythrocytedeformability.This
ﬁnding underlines that physiological levels of proinsulin C-
peptide are already sufﬁcient to saturate C-peptide effects on
erythrocyte deformability.
Inordertohypothesizethepotentialmechanismoftheeffect
of proinsulin C-peptide, previous studies concerning Na+,K+-
ATPase activity in renal tubular cells and erythrocytes of di-
abetic subjects are of considerable interest (Ohtomo et al.,
1996,1998;FinottiandPalatini,1986).Ohtomoandcolleagues
(1998, 1999) were able to show that the attenuated activitity of
Na+,K+-ATPase activity in renal tubular segments of diabetic
rats was able to be restored by proinsulin C-peptide. On the
other hand, attenuation of Na+,K+-ATPase activity has been
demonstrated to correlate with decreased deformability in ery-
throcytesoftype1diabetespatients(FinottiandPalatini,1986).
It is very speculative to explain the underlying mecha-
nism based upon these results but impaired Na+,K+-ATPase
activity may contribute to the decrease of erythrocyte de-
formability by increasing the intracellular sodium concentra-
tion, with subsequent intracellular accumulation of free cal-
cium ions due to competition in transmembranous exchange
(Mazzanti et al., 1990). These abnormalities in calcium home-
ostasis are known to enhance spectrin dimer-dimer interac-
tion and spectrin–protein 4.1–actin interaction (Takakuwa and
Mohandes, 1988; Schischmanoff et al., 1995). The latter is
being promoted by adducin, a membrane skeleton–associated
calmodulin-binding protein (Gardner and Bennett, 1986).
Hence, this effect of C-peptide on erythrocyte deformability
is probably mediated by Na+,K+-ATPase restoration. Pretreat-
ment of erythrocytes from type 1 diabetic patients with oubain,
an Na+,K+-ATPase inhibitor, completely abolished C-peptide
effects on erythrocyte deformability. Therefore it seems likely
that the restoration of erythrocyte deformability by proinsulin
C-peptide is mediated by an increase of Na+,K+-ATPase
activity.
Recent studies with C-peptide fragments have shown that
these effects of C-peptide on erythrocyte deformability are de-
pendent on the presence of the C-terminal sequence of amino
acids of the molecule (Hach et al., 2002).
IN VIVO INVESTIGATIONS
Effects of C-peptide on Microvascular
Blood Flow
C-peptide has shown to inﬂuence microvascular blood ﬂow
by mediating vascular tonicity and increasing erythrocyte de-
formability. Therefore, it seems conceivable that C-peptide it-
self might exert biological effects on microvascular function
and might have an implication in the development of microvas-
cular complications in patients with type 1 diabetes mellitus.
In early in vitro studies, C-peptide had been shown to cause
active vasodilatation of the microvasculature and to enhance
recruitment of capillaries (Lindstrom et al., 1996). These re-
sults were conﬁrmed in a study by Jensen and Messina (1999),
which investigated the effect of C-peptide on skeletal muscle




imal effect within 15 minutes. Interestingly, addition of insulin
at a concentration of 1 µU/mL, which had no vascular effect
by its own, clearly enhanced the vascular effect of C-peptide.
Therefore, it seems likely that insulin plays a permissive role
in the vascular effects of C-peptide. Addition of L-NNA, an
NOS inhibitor, completely abolished the vasodilating response
of the microvessels, further indicating the role of NO in the
mechanism of C-peptide action.
In a study done by Ido and colleagues (1997), beneﬁcial
effects of C-peptide supplementation could be documented in
several vascular beds in diabetic rats. In their study, biosyn-
thetic human C-peptide were given subcutaneously twice daily
for 5 weeks in control rats and streptozotocin-induced diabetic
rats. Highly supraphysiological peak plasma C-peptide levels
between 9 and 10 nM were reached. C-peptide markedly atten-
uated the diabetes-induced increase in blood ﬂow in the ante-
rior uvea, retina, and sciatic nerve. In addition, C-peptide pre-
vented an increased 125I-labeled albumin permeation in retina,
nerve, and in the aorta. The improvement in microvascular
blood ﬂow was accompanied by an increase in caudal motor
nerve conduction velocity. No effect of C-peptide, neither on
microvascular blood ﬂow nor on motor nerve conduction ve-
locity, could be observed in the healthy control rats. Cotter and
Cameron (2002) observed the vascular effects of C-peptide on
sciatic endoneurial blood ﬂow in streptozotocin diabetic rats at
physiologicalC-peptideconcentrations.Inthisstudy,C-peptide




conduction velocity by 62% and sensory nerve conduction ve-
locity by 78%. Cotreatment with L-NNA markedly attenuated
the C-peptide effects on endoneurial blood ﬂow and nerve con-
duction velocities.
Interestingly,atsupraphysiologicalC-peptidelevelsreached
in the study of Ido and colleagues (1997), a reverse se-
quenceofC-peptide(retro-C-peptide)wasalmostaseffectiveas58 T. FORST AND T. KUNT
native C-peptide with regard to the vascular effects. In con-
trast, a scrambled peptide in which the amino acid com-
position was identical to that of native C-peptide, but the
sequence was randomized, was found to be ineffective. In-
tact human proinsulin and both split forms des(31,32) and
des(64,65) were thought to be without any biological activ-
ity. Amino acid residues in the midportion of human C-peptide
were found to be critical for the observed vascular functions of
the peptide. From these ﬁndings, Ido and colleagues concluded
that the effect of C-peptide might be mediated by a nonchiral
mechanism rather than by stereospeciﬁc receptors on the cell
membrane.
In an investigation by Johanssen and colleagues (1992), the
effect of C-peptides on skeletal muscle blood ﬂow were ob-




ﬂow and capillary diffusion capacity of the exercising forearm
were approximately 30% lower compared to the healthy con-
trol subjects. Intravenous administration of C-peptide during
exercise increased forearm blood ﬂow by 27% and capillary
diffusion capacity by 52% to levels similar to those observed
in the healthy controls. No signiﬁcant changes in blood ﬂow
could be observed in the healthy controls receiving C-peptide
or in the diabetic patients receiving placebo infusions.
In accordance with the observed improvements in skele-
tal muscle blood ﬂow, forearm oxygen and glucose uptake
increased markedly after C-peptide administration in type 1
diabetic patients. This study was the ﬁrst to demonstrate that
C-peptide administration has a signiﬁcant hemodynamic and
metabolic effect in human diabetic patients who lack endoge-
neous C-peptide secretion, whereas no such effect could be
observed in healthy subjects.
As already mentioned before, C-peptide may act in syner-
gism with other hormones. Neuropeptide Y (NPY) is a vaso-
constrictor peptide that is costored with noradrenaline in sym-
pathetic perivascular nerves. Type 1 diabetic patients have a
blunted release of both noradrenaline and NPY during exercise
(Ahlborg and Lundberg, 1996). Therefore, in a subsequent
study,JohanssonandPernow(1999)examinedwhetherthereis
an interference between NPY and C-peptide on forearm blood
ﬂow measured by venous occlusion plethysmography. During
administration of C-peptide, forearm blood ﬂow increased by
25%. The subsequent NPY infusion resulted in an enhanced
vasconstrictor response of NPY. Forearm vascular resistance
wasinverselyreducedduringC-peptideadministration(−17%)
atbaselineandduringadministrationofNPY.Again,noeffects
of C-peptide, neither before nor during NPY administartion,
could be observed in healthy controls.
Skin blood ﬂow is found to be altered early after the diag-
nosis of diabetes mellitus (Tooke et al., 1985b; Ewald et al.,
1981; Flynn and Tooke, 1992). The capillary circulation is
functionally situated in parallel to the arteriovenous shunts and
is thought to have the primary function of skin nutrition. It
has been estimated that 80% to 90% of total skin blood ﬂow
passesthroughthermoregulatoryarteriovenousshuntsanddoes
not enter the capillary bed (Jorneskog et al., 1995a, 1995b;
Boultonetal.,1982).Althoughtotalskinperfusionisincreased
in diabetes mellitus, nutritional capillary skin blood ﬂow was
showntobereducedindiabeticpatients(Jorneskogetal.,1990,
1995a, 1995b). This discrepancy between nutritional and to-
tal skin microcirculation has been explained by a shunting of
blood through arteriovenous anastomosis (Boulton et al., 1982;
Flynn and Tooke, 1992). In one of our own investigations, we
examined the effect of human C-peptide on skin microcircula-
tion in type 1 diabetic patients and in healthy controls (Forst
et al., 1998). In our study, total skin perfusion was measured by
laserdopplerﬂuxmetry and nutritive capillary blood ﬂow was
investigated by intravital videophotometric capillaroscopy. At
baseline, nutritive capillary blood ﬂow was signiﬁcantly lower
in type 1 diabetic patients, compared with the control group.
During C-peptide supplementation in type 1 diabetic patients,
a steady increase in capillary blood ﬂow could be observed,
reaching values not different from the healthy control group
after 60 minutes. No signiﬁcant change in capillary blood ﬂow
could be observed in the healthy control group or in type 1
diabetic patients during placebo infusion. The capillary blood
ﬂowatbaselineandafter60minutesofinfusioninthedifferent
groups are given in Figure 6. Thirty minutes after termination
of C-peptide infusion, the capillary blood ﬂow declined again
to values not different from baseline.
A linear relationship was found between plasma C-peptide
levels and the capillary blood ﬂow velocity (r = .401, P <
.0001). No impact of C-peptide could be observed on subpap-
illary blood ﬂow measured by laserdopplerﬂuxmetry, neither
in the type 1 diabetic group nor in the control group. In addi-
tion, spectral analysis of ﬂow motion revealed no signiﬁcant
inﬂuence of C-peptide on neurovascular control.
The increase in plasma C-peptide levels was associated
with an increase in nutritional capillary blood ﬂow, however,
did not affect total skin blood ﬂow in insulin-dependent
diabetes mellitus (IDDM) patients. These ﬁndings suggest
a redistribution of skin microvascular blood ﬂow into the
nutritive capillary circulation during C-peptide administration.
The increase in capillary blood ﬂow, thus, may improve the
exchange of nutrients, oxygen, and waste products in the skin.
In healthy subjects, peak C-peptide levels are usually seen
after the ingestion of food, with a complementary increase of
glucose and nutrients in the blood stream. The postprandialC-PEPTIDE AND BLOOD FLOW AND HEMORHEOLOGY 59
FIGURE 6
Nutritive capillary blood ﬂow at baseline and 60 minutes after infusion of C-peptide (8 pmol/kg/min) in the different groups.
distribution of microvascular blood ﬂow into nutritive vascular
compartments may fulﬁll physiological requirements and the
lack of endogenous C-peptide may lead to disturbances in
nutritive tissue metabolism.
Also,insulinhasbeenshowntoincreaseskincapillaryblood
ﬂow (Tooke et al., 1985a; Flynn et al., 1992) by modulation of
endothelium-derived vasoactive substances, such as endothe-
lin, NO, or adenosine (Poldermann et al., 1996). However, in
our study, there was no signiﬁcant difference in insulin levels
betweenthedifferentgroupsandobservationperiodsand,there-
fore, the observed effects on microvascular blood ﬂow may be
attributed to the changes in C-peptide levels.
Effects of C-peptide on Endothelial Cell
Function and Endothelium–Blood Cell
Interactions In Vivo
A couple of the previously described investigations gave
evidence to the hypothesis that the vasodilatatory actions of
C-peptide might be due to an effect on endothelial cells. The
most widely known endothelium derived relaxing factor, NO,
is released from endothelial cells in response to shear stress or
stimulation of different receptors for a variety of neurohumoral
mediatorsontheendothelialcellsurface(CohenandVanhoutte,
1995).Asdescribedintheprevioussection,C-peptidehasbeen
shown to increase NO secretion in endothelial cells, which was
clearly Ca2+ dependent (Kunt et al., 1998b, 1998c).
Flow mediated vasodilatation (FMV) depends on an intact
endothelial function and is considered to be mediated by NO
(Palmer et al., 1987). In type 1 diabetes, FMV is known to be
decreased in conduit arteries, such as the brachial or femoral
arteries (Elliott et al., 1993; Johnstone et al., 1993; Clarkson
et al., 1996).
Fernqvist-Forbes and colleagues (2001) studied the effect
of C-peptide administration on ﬂow-mediated vasodilatation
(FMV) in response to reactive hyperaemia in type 1 diabetic
patients. In addition, the arterial dilatation to glyceryl trini-
trate, which is an endothelium-independent marker of vascu-
lar smooth muscle function, was investigated. When compared
with a healthy control group, the type 1 diabetic patients re-
vealed a lower ﬂow-mediated dilatation. Following C-peptide
administration,basalbloodﬂowinthebrachialarteryincreased
byapproximately35%comparedwiththecontrolmeasurement
when NaCl was infused. In response to reactive hyperemia,
C-peptide administration resulted in a signiﬁcant increase in
forearm blood ﬂow compared with the basal state and with the
control day. During saline infusion, no signiﬁcant changes in
forearm blood ﬂow could be observed. No signiﬁcant changes
after glyceryltrinitrate, neither during C-peptide infusion nor
during saline infusion, could be obtained. In addition, a slight,
but signiﬁcant, increase in the left ventricular systolic function
could be found in type 1 diabetic patients during C-peptide in-
fusion, whereas no effect was observed during NaCl infusion.
In conclusion, this study underlines an endothelium-dependent
mechanisminC-peptideaction.NoeffectofC-peptidecouldbe
observed on endothelium-independent blood ﬂow regulation.
Inoneofourownstudies,weexploredtheeffectofC-peptide
onacetylcholine-evokedvasodilatationinskinmicrocirculation
in type 1 diabetic patients (Forst et al., 2000). Acetylcholine
elicts vasodilatation through a stimulation of eNOS, with an60 T. FORST AND T. KUNT
FIGURE 7
Cyclic guanyl monophosphate (cGMP) at baseline and after 60 minutes (3 pmol/kg/min) and 120 minutes (10 pmol/kg/min) of
C-peptide or placebo infusion.
FIGURE 8
Na+,K+-ATPase activity at baseline and after 60 minutes (3 pmol/kg/min) and 120 minutes (10 pmol/kg/min) of C-peptide
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increased NO production and a subsequent increase of cyclic
GMPinvascularsmoothmuscle(Calles-EscandonandCipolla,
2001; Morris et al., 1995; Pieper et al., 1997; McNally et al.,
1994). In this study, the skin microvascular response was mea-
sured by laser doppler ﬂuxmetry and acetylcholine was ap-
plied to the dorsum of the foot by the technique of iontophore-
sis. C-peptide was infused intravenously at a concentration of
3 pmol−1 kg−1 min−1 for the ﬁrst 60 minutes and at a con-
centration of 10 pmol kg−1 min−1 for another 60 minutes. At
baselineandafter60and120minutes,thelaserdopplerﬂuxre-
sponse to acetylcholine was measured and blood samples were
taken for the measurement of plasma cyclic GMP levels. The
laserdopplerﬂux response to acetylcholine increased by 133%
during the low infusion rate and by 80% during the high infu-
sion rate of C-peptide. The increase in the laser doppler ﬂux
response to acetylcholine was signiﬁcant compared to base-
line and to a saline infusion. No signiﬁcant difference in the
laserdopplerﬂux response to acetylcholine could be observed
between the different C-peptide concentrations. Cyclic GMP
levels are illustrated in Figure 7.
Therewasfounda14%increaseinplasmacyclicGMPlevels
during the low infusion rate of C-peptide and a 23% increase in
plasma cyclic GMP levels during the high infusion rate of C-
FIGURE 9
Postulated molecular mechanism of C-peptides vascular and hemorheological effects.
peptide (P <. 05). No signiﬁcant changes in plasma C-peptide
levels could be observed during NaCl infusion.
Effects of C-peptide on Erythrocyte
NA+,K+-ATPase Activity
In a recent investigation by Dufayet and colleagues (1998),
erythrocyte Na+,K+-ATPase activity was compared between
type 1 and type 2 diabetic patients. Although in type 1 diabetic
patients, a clear reduction in erythrocyte Na+,K+-ATPase
activity could be observed, type 2 diabetic patients exhibited
a wide range of individual Na+,K+-ATPase activity readings,
presenting some patients with very low Na+,K+-ATPase
activity and others with Na+,K+-ATPase activity within the
physiological range. It appeared that erythrocyte Na+,K+-
ATPase activity was signiﬁcantly lower in those type 2 patients
treated with insulin compared with those on oral treatment.
Also in the former, Na+,K+-ATPase activity was comparable
to those in type 1 diabetic patients. The authors suggested
that treatment with exogenous insulin in type 2 diabetic
patients could negatively regulate Na+,K+-ATPase activity.
Type 2 diabetic patients were older, had a longer diabetes
duration, poorer glycemic control, and lower C-peptide
levels, but only C-peptide was independently correlated with62 T. FORST AND T. KUNT
erythrocyte Na+,K+-ATPase activity. In an in vitro study by
Djemli-Shiplolye and colleagues (2000), incubation of ery-
throcytes from type 1 diabetic patients with C-peptide showed
a signiﬁcant increase in erythrocyte Na+,K+-ATPase activity.
In one of our own studies, intravenous infusion of C-peptide in
a concentration of 3 pmol/kg/min for 60 minutes and at a con-
centration of 10 pmol/kg/min for additional 60 minutes in type
1 diabetic patients resulted in a steady increase in erythrocyte
Na+,K+-ATPase activity (Figure 8), whereas infusion of NaCl
was without any signiﬁcant effect (Forst et al., 2000).
CONCLUSIONS
ThepotentialroleofC-peptideasanbiologicallyactivepep-
tide has been controversially discussed in the past on the basis
of studies being contradictory concerning the impact of this
cleavage product of insulin. Recent studies, in turn, demon-
strated unanimously that C-peptide is biologically active by
predominantly modulating blood ﬂow. Thus, there is evidence
thatC-peptideimprovesredcelldeformabilityandmicrovascu-
lar blood ﬂow in type 1 diabetes. The underlying mechanisms,
initiated by binding to an G-protein–coupled receptor, involve
at least the activation of eNOS and the activation of Na+,K+-
ATPase and are therefore calcium dependent and ouabain sen-
sitive. The postulated mechanism by which C-peptide interact
with microvascular blood ﬂow is illustrated in Figure 9.
Therefore, it is fairly reasonable to advance the hypothe-
sis that C-peptide supplementation in a state of C-peptide deﬁ-
ciency(e.g.,intype1diabetes)maybebeneﬁcialinordertopre-
vent nonglucotoxic vascular complications. The improvement
of the formerly impaired hemorrheological properties of vas-
cular regulation as demonstrated by these investigations need
certainly further support by well-designed prospective inter-
ventional clinical trials monitoring the progression of vascular
complications in a long-term follow-up.
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